5:43 PM
 | 
Jun 17, 2019
 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint
VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs. three doses of Engerix-B from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at day 196 in the Phase III PROTECT trial. The HBV vaccine, which contains the virus’ S, preS1 and preS2 surface antigens, met PROTECT's co-primary endpoints. VBI plans to reassess non-inferiority by integrating data from PROTECT and the Phase III CONSTANT trial, for which data are expected around year end.

ArQule to begin registrational portion of AKT inhibitor trial next quarter
ArQule Inc. (NASDAQ:ARQL) gained $1.38 (17%) to $9.58...

Read the full 531 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >